ABL1 BCR::ABL Y253H

CI-VAR-00005091Explore in graph →CIViC 1025

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Chronic Myeloid Leukemia, BCR-ABL1 Positive2
ABL1 BCR::ABL Y253H	Imatinib	Predictive	C	Supports Resistance	2	rejected	EID7829 One chronic myeloid leukemia patient in chronic phase with the BCR-ABL1 fusion and the Y253H secondary variant in 11/11 clones had complete cytogenetic best cytogenetic response to imatinib before bec… (full text at CIViC) PMID 16775234 · Talpaz et al., 2006 · Open in CIViC	civic
ABL1 BCR::ABL Y253H	Imatinib Mesylate	Predictive	D	Supports Resistance	2	rejected	EID6279 In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib to identify resistance mutations. The Y253H mutation in th… (full text at CIViC) PMID 16772610 · Bradeen et al., 2006 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.